Ellsworth Advisors LLC Acquires New Position in GeneDx Holdings Corp. $WGS

Key Points

• Ellsworth Advisors LLC has acquired 15,965 shares of GeneDx Holdings Corp., valued at approximately $1,414,000, representing a 0.06% stake in the company.
• Insider trading activity includes CFO Kevin Feeley selling 378 shares, reducing his position by 8.45%, while Director Jason Ryan sold 38,072 shares, which marked a 26.93% decrease in his holdings.
• GeneDx reported earnings of $0.50 per share, surpassing the estimate of $0.10, with revenue reaching $102.69 million for the quarter, exceeding analyst expectations of $86.00 million.

Ellsworth Advisors LLC purchased a new stake in shares of GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) in the first quarter, according to the company in its most recent filing with the SEC. The firm purchased 15,965 shares of the company's stock, valued at approximately $1,414,000. Ellsworth Advisors LLC owned about 0.06% of GeneDx at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of WGS. GAMMA Investing LLC lifted its position in GeneDx by 151.7% during the first quarter. GAMMA Investing LLC now owns 438 shares of the company's stock valued at $39,000 after purchasing an additional 264 shares during the last quarter. Lazard Asset Management LLC bought a new stake in GeneDx during the fourth quarter valued at approximately $35,000. US Bancorp DE lifted its position in GeneDx by 3,223.5% during the first quarter. US Bancorp DE now owns 565 shares of the company's stock valued at $50,000 after purchasing an additional 548 shares during the last quarter. Comerica Bank bought a new stake in shares of GeneDx during the 4th quarter worth $50,000. Finally, KBC Group NV bought a new stake in shares of GeneDx during the 1st quarter worth $81,000. Institutional investors own 61.72% of the company's stock.

Analyst Ratings Changes

WGS has been the subject of a number of research analyst reports. Guggenheim reaffirmed a "buy" rating and set a $115.00 price objective (up from $88.00) on shares of GeneDx in a report on Monday, June 30th. Wall Street Zen raised GeneDx from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Wells Fargo & Company boosted their target price on GeneDx from $78.00 to $95.00 and gave the stock an "equal weight" rating in a research report on Wednesday, July 30th. Finally, Piper Sandler boosted their target price on GeneDx from $120.00 to $140.00 and gave the stock an "overweight" rating in a research report on Thursday, September 11th. Six analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $104.13.

Insider Buying and Selling at GeneDx

In related news, CFO Kevin Feeley sold 5,278 shares of the stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $93.00, for a total value of $490,854.00. Following the completion of the transaction, the chief financial officer directly owned 3,392 shares in the company, valued at $315,456. This trade represents a 60.88% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jason Ryan sold 38,072 shares of the firm's stock in a transaction dated Wednesday, August 27th. The shares were sold at an average price of $127.30, for a total transaction of $4,846,565.60. Following the sale, the director owned 103,284 shares of the company's stock, valued at approximately $13,148,053.20. This represents a 26.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 561,641 shares of company stock valued at $67,551,904 in the last quarter. 29.60% of the stock is owned by insiders.

GeneDx Trading Up 0.5%

NASDAQ WGS traded up $0.59 during trading on Tuesday, hitting $122.63. The company had a trading volume of 390,606 shares, compared to its average volume of 1,011,207. The company has a current ratio of 2.87, a quick ratio of 2.70 and a debt-to-equity ratio of 0.19. GeneDx Holdings Corp. has a one year low of $35.88 and a one year high of $136.00. The company has a market cap of $3.52 billion, a price-to-earnings ratio of 2,452.56 and a beta of 2.03. The company's fifty day moving average is $108.36 and its 200-day moving average is $92.01.

GeneDx (NASDAQ:WGS - Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The company reported $0.50 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.10 by $0.40. GeneDx had a net margin of 0.39% and a return on equity of 16.51%. The company had revenue of $102.69 million during the quarter, compared to the consensus estimate of $86.00 million. GeneDx has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that GeneDx Holdings Corp. will post 0.97 earnings per share for the current year.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.